Elisabeth Potts Dellon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elisabeth Potts Dellon has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Dio Kavalieratos
Emory University, Atlanta, Georgia, USA
6 shared publications Mary G. Prieur
Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, NC USA; Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC USA
5 shared publications- Jane Lowers
Emory University
4 shared publications Albert Faro
Cystic Fibrosis Foundation, Bethesda, Maryland
3 shared publications- Albert Faro
Cystic Fibrosis Foundation, Bethesda, MD, USA
3 shared publications - Charles R. Esther
Pediatric Pulmonology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
3 shared publications
Latest Publications
- 10 October 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 248, 108407
Mental health and transplantation in cystic fibrosis
- 10 October 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 248, 108407
Mental health and transplantation in cystic fibrosis
- 25 July 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (4) , 637-638
After the honeymoon: Real world experiences with CFTR modulators
- 25 July 2025
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 24 (4) , 637-638
After the honeymoon: Real world experiences with CFTR modulators
- 22 March 2024
- Published by Wiley in Pediatric Pulmonology
- Vol. 59 (6) , 1795-1797
Elevated creatine phosphokinase and rhabdomyolysis associated with elexacaftor/tezacaftor/ivacaftor use in cystic fibrosis
- 22 March 2024
- Published by Wiley in Pediatric Pulmonology
- Vol. 59 (6) , 1795-1797
Elevated creatine phosphokinase and rhabdomyolysis associated with elexacaftor/tezacaftor/ivacaftor use in cystic fibrosis
- 11 March 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (5) , 831-835
Symptoms and quality of life in adults with cystic fibrosis: A cross-sectional analysis of the InSPIRe:CF trial
- 11 March 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (5) , 831-835
Symptoms and quality of life in adults with cystic fibrosis: A cross-sectional analysis of the InSPIRe:CF trial
- 8 March 2024
- Published by Wiley in Pediatric Pulmonology
- Vol. 59 (6) , 1614-1621
Exploring perceptions of and decision‐making about CFTR modulators
Introduction: Cystic fibrosis (CF) treatment has increasingly focused on highly effective modulators. Despite measurable benefits of modulators, there is little guidance for CF care team members on providing education and support to patients regarding initiation of these therapies. We aimed to explore patient, caregiver, and clinician perceptions of modulators and influences on decisions about starting cystic fibrosis transmembrane regulator (CFTR) modulators.Methods: We conducted semistructured interviews with CF clinicians, adults with CF, and caregivers of children with CF. We reviewed audio recordings and coded responses to identify central themes.Results: We interviewed 8 CF clinicians, 9 adults with CF, and 11 caregivers of children with CF. Themes centered on emotional responses to modulator availability, influences on decision‐making, concerns about side effects, impact of modulators on planning for the future, the benefits of the multidisciplinary CF care team in supporting treatment decisions, and the unique needs of people with CF who are not eligible for modulators. Clinicians described changes in conversations about modulators since the approval of elexacaftor/tezacaftor/ivacaftor, specifically greater willingness to prescribe with less nuanced conversations with patients and/or caregivers regarding their use.Conclusion: Based on perspectives and experiences of CF clinicians, adults with CF, and caregivers of children with CF, we suggest clinicians approach conversations about CFTR modulators thoughtfully and thoroughly, utilizing the multidisciplinary model of CF care in exploring patient and caregiver emotions while filling in knowledge gaps, asking about treatment goals beyond potential clinical benefit, and having compassionate conversations with those who are ineligible for modulators.
- 8 March 2024
- Published by Wiley in Pediatric Pulmonology
- Vol. 59 (6) , 1614-1621
Exploring perceptions of and decision‐making about CFTR modulators
Introduction: Cystic fibrosis (CF) treatment has increasingly focused on highly effective modulators. Despite measurable benefits of modulators, there is little guidance for CF care team members on providing education and support to patients regarding initiation of these therapies. We aimed to explore patient, caregiver, and clinician perceptions of modulators and influences on decisions about starting cystic fibrosis transmembrane regulator (CFTR) modulators.Methods: We conducted semistructured interviews with CF clinicians, adults with CF, and caregivers of children with CF. We reviewed audio recordings and coded responses to identify central themes.Results: We interviewed 8 CF clinicians, 9 adults with CF, and 11 caregivers of children with CF. Themes centered on emotional responses to modulator availability, influences on decision‐making, concerns about side effects, impact of modulators on planning for the future, the benefits of the multidisciplinary CF care team in supporting treatment decisions, and the unique needs of people with CF who are not eligible for modulators. Clinicians described changes in conversations about modulators since the approval of elexacaftor/tezacaftor/ivacaftor, specifically greater willingness to prescribe with less nuanced conversations with patients and/or caregivers regarding their use.Conclusion: Based on perspectives and experiences of CF clinicians, adults with CF, and caregivers of children with CF, we suggest clinicians approach conversations about CFTR modulators thoughtfully and thoroughly, utilizing the multidisciplinary model of CF care in exploring patient and caregiver emotions while filling in knowledge gaps, asking about treatment goals beyond potential clinical benefit, and having compassionate conversations with those who are ineligible for modulators.
- 3 November 2023
- Published by Elsevier
- p. 515-521
What Are Special Considerations for Patients With Cystic Fibrosis?
- 3 November 2023
- Published by Elsevier
- p. 515-521
What Are Special Considerations for Patients With Cystic Fibrosis?
- 9 September 2023
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 11 (10) , 861-863
End-of-life care in cystic fibrosis in the era of new therapies
- 9 September 2023
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 11 (10) , 861-863
End-of-life care in cystic fibrosis in the era of new therapies
- 30 May 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (6) , 1100-1103
Clinician perspectives on barriers and solutions to symptom management in cystic fibrosis
- 30 May 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (6) , 1100-1103
Clinician perspectives on barriers and solutions to symptom management in cystic fibrosis
- 13 August 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (2) , 352-355
Prevalence of unmet pain and symptom management needs in adults with cystic fibrosis
- 13 August 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 22 (2) , 352-355
Prevalence of unmet pain and symptom management needs in adults with cystic fibrosis